ArticleWorld journal of gastrointestinal pathophysiology2010
Low-grade inflammation plays a pivotal role in gastrointestinal dysfunction in irritable bowel syndrome.
Article in World journal of gastrointestinal pathophysiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 105 citations in OpenAlex.
- Effects of fructan and gluten on gut microbiota in individuals with self-reported non-celiac gluten/wheat sensitivity-a randomised controlled crossover trial.BMC medicine · 2024Trial
- Effects of a low FODMAP diet on gut microbiota in individuals with treated coeliac disease having persistent gastrointestinal symptoms - a randomised controlled trial.The British journal of nutrition · 2023Trial
- Evaluation of Benefit and Tolerability of IQP-CL-101 (Xanthofen) in the Symptomatic Improvement of Irritable Bowel Syndrome: A Double-Blinded, Randomised, Placebo-Controlled Clinical Trial.Phytotherapy research : PTR · 2017Trial
- The Impact of Irritable Bowel Syndrome on Spine Surgery Outcomes: A Comprehensive Narrative Review.Journal of clinical medicine · 2026Review
- Non-Invasive Multimarker Strategy Combining IL-17A, Neutrophil-Albumin Ratio, and Fecal Calprotectin for Accurate Discrimination of IBD from IBS-D.International journal of molecular sciences · 2026Article
- Carotenoids modulate fermentation of inulin ex vivo in IBS and overweight adult gut microbiota.BMC microbiology · 2026Article
- Gut-Brain Inflammation and Disrupted Homeostasis Due to Activation of Mast Cells and Microglia.International journal of molecular sciences · 2026Review
- Macrophage Immune-Competent Colon Assembloids for Functional Interrogation of Neuroinflammation-Induced Colonic Dysmotility.Gastro hep advances · 2026Article
- Gut microbiota profiles associated with persistent anal HPV infection in men who have sex with men.BMC infectious diseases · 2025Article
- Adherence to EAT-Lancet diet and odds of irritable bowel syndrome and functional dyspepsia: the Isfahan functional disorders (ISFUN) study.Nutrition journal · 2025Article
- Could the Therapeutic Effect of Physical Activity on Irritable Bowel Syndrome Be Mediated Through Changes to the Gut Microbiome? A Narrative and Hypothesis Generating Review.Neurogastroenterology and motility · 2025Review
- Therapeutic Potential of Flavonoids and Flavonoid-Rich Compounds in Irritable Bowel Syndrome.Drug design, development and therapy · 2025Review
- Long-Term Implicit Epigenetic Stress Information in the Enteric Nervous System and its Contribution to Developing and Perpetuating IBS.Current neuropharmacology · 2024Review
- Non-invasive neuromodulation: an emerging intervention for visceral pain in gastrointestinal disorders.Bioelectronic medicine · 2023Review
- Evaluating the Potential of Casein Glycomacropeptide in Adult Irritable Bowel Syndrome Management: A Pilot Study.Nutrients · 2023Article
- The Role of Bovine Kappa-Casein Glycomacropeptide in Modulating the Microbiome and Inflammatory Responses of Irritable Bowel Syndrome.Nutrients · 2023Review
- Faecalibacterium: a bacterial genus with promising human health applications.FEMS microbiology reviews · 2023Review
- Early life adverse exposures in irritable bowel syndrome: new insights and opportunities.Frontiers in pediatrics · 2023Review
- Gastrointestinal symptoms in COVID-19.Przeglad gastroenterologiczny · 2023Review
- Infantile Colic and the Subsequent Development of the Irritable Bowel Syndrome.Journal of neurogastroenterology and motility · 2022Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pathogenesis of irritable bowel syndrome (IBS) is considered to be multifactorial and includes psychosocial factors, visceral hypersensitivity, infection, microbiota and immune activation. It is becoming increasingly clear that low-grade inflammation is present in IBS patients and a number of biomarkers have emerged. This review describes the evidence for low-grade inflammation in IBS and explores its mechanism with particular focus on gastrointestinal motor dysfunction. Understanding of the immunological basis of the altered gastrointestinal motor function in IBS may lead to new therapeutic strategies for IBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.